View Older Stories View More Recent Stories

Nov 15, 2024 05:29PM Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Nov 12, 2024 07:06AM Syndax Pharmaceuticals (SNDX) Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Nov 12, 2024 07:00AM Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Nov 5, 2024 04:01PM Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 5, 2024 09:01AM Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
Nov 5, 2024 09:00AM Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
Nov 5, 2024 09:00AM Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
Nov 4, 2024 04:02PM Syndax Pharmaceuticals (SNDX) and Royalty Pharma (RPRX) Enter $350M Royalty Funding Agreement for Niktimvo
Nov 4, 2024 04:01PM Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
Nov 1, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 1, 2024 07:00AM Syndax Announces Participation in November Investor Conferences
Oct 29, 2024 07:00AM Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
Oct 4, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 18, 2024 05:17PM Syndax (SNDX) and Incyte (INCY) Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo
Sep 18, 2024 05:15PM Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
Sep 6, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 14, 2024 05:34PM Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Aug 12, 2024 07:02AM Syndax Pharmaceuticals (SNDX) Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
Aug 12, 2024 07:00AM Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
Aug 5, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 1, 2024 04:05PM Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
Jul 29, 2024 07:01AM Syndax Pharmaceuticals (SNDX) Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
Jul 29, 2024 07:01AM Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
Jul 25, 2024 07:00AM Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
Jul 5, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 17, 2024 09:00AM Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Jun 14, 2024 07:00AM Syndax Pharmaceuticals (SNDX) Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib
Jun 14, 2024 07:00AM Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
Jun 10, 2024 07:30AM Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
Jun 6, 2024 07:01AM Syndax Pharmaceuticals (SNDX) to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
Jun 6, 2024 07:00AM Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
Jun 5, 2024 07:00AM Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 3, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 15, 2024 04:06PM Syndax Pharmaceuticals (SNDX) Appoints Aleksandra Rizo to its Board
May 15, 2024 04:05PM Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
May 9, 2024 07:00AM Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
May 8, 2024 07:06AM Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
May 3, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 1, 2024 07:00AM Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Apr 10, 2024 04:05PM Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Apr 8, 2024 07:22AM Syndax Pharmaceuticals (SNDX) Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Apr 8, 2024 07:00AM Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Apr 5, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 28, 2024 07:00AM Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
Mar 26, 2024 04:06PM Syndax Pharmaceuticals (SNDX) Granted FDA Priority Review of NDA for Revumenib
Mar 26, 2024 04:05PM Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Mar 18, 2024 07:03AM Syndax Pharmaceuticals (SNDX) names Steven Closter as Chief Commercial Officer
Mar 18, 2024 07:00AM Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Mar 1, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 27, 2024 04:05PM Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
View More Recent Stories View Older Stories